Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells.
- Author:
Karyn Muzinga NDOLO
1
;
Kyeong Ryang PARK
;
Hyo Jeong LEE
;
Kyoung Bin YOON
;
Yong Chul KIM
;
Sun Young HAN
Author Information
- Publication Type:Original Article
- Keywords: Aurora kinase A; Indirubin derivative; Colorectal cancer
- MeSH: Aurora Kinase A*; Cell Survival; Colorectal Neoplasms*; Cytokinesis; Histones; HT29 Cells; Humans*; In Vitro Techniques; Mitosis; Phosphorylation; Phosphotransferases; Prognosis
- From:Immune Network 2017;17(2):110-115
- CountryRepublic of Korea
- Language:English
- Abstract: Aurora kinase A plays an essential role in mitosis including chromosome separation and cytokinesis. Aberrant expression and activity of Aurora kinase A is associated with numerous malignancies including colorectal cancer followed by poor prognosis. The aim of this study is to determine the inhibitory effects of LDD970, an indirubin derivative, on Aurora kinase A in HT29 colorectal cancer cells. In vitro kinase assay revealed that, LDD970 inhibited levels of activated Aurora kinase A (IC₅₀=0.37 mM). The inhibitory effects of LDD970 on Aurora kinase A, autophosphorylation and phosphorylation of histone H3 (Ser10), were confirmed by immunoblot analysis. Moreover, LDD970 inhibited migration of HT29 cells and upregulated apoptosis-related protein cleaved PARP. In cell viability assay, LDD970 was observed to suppress HT29 cell growth (GI₅₀=4.22 µM). Although further studies are required, results of the present study suggest that LDD970 provide a valuable insight into small molecule indirubin derivative for therapeutic potential in human colorectal cancer.
